Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association – GAA) document
暂无分享,去创建一个
L. Boulet | G. Canonica | J. Bernstein | D. Solé | K. Kowal | N. Rosário | S. Mihaicuta | I. Ansotegui | C. Nunes | P. Steiropoulos | F. Braido | I. Baiardini | A. Bikov | P. Santus | J. Correia de Sousa | A. Tiotiu | A. Emelyanov | Filippo Cosini | J. Ivancevich | H. Chong-Neto | I. Kaidashev | M. Labor | D. Nedeva | G. Guidos-Fogelbach | Sylvia Novakova | Marilyn Urrutia Pereira | Plamela Novakova | Laura Vrzy | L. Dubuske | M. Urrutia Pereira | S. Novakova | L. DuBuske
[1] H. Sagara,et al. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study , 2021, Current medical research and opinion.
[2] P. O'Byrne,et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. , 2021, JAMA.
[3] “Real-life” management of patients with severe asthma in the biologics era: Can we do better?☆ , 2021, The World Allergy Organization journal.
[4] H. Sagara,et al. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population , 2021, BMJ Open Respiratory Research.
[5] Shuying Yang,et al. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN) , 2021, Clinical Pharmacokinetics.
[6] H. Kerstjens,et al. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. , 2021, Respiratory medicine.
[7] L. Boulet,et al. Manifesto on united airways diseases (UAD): an Interasma (global asthma association – GAA) document , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.
[8] J. Virchow,et al. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post-hoc analyses. , 2021, The Journal of allergy and clinical immunology.
[9] F. Cardoso,et al. Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto , 2021, Breast.
[10] H. Watz,et al. Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial , 2020, ERJ Open Research.
[11] Ju-Young Shin,et al. Cost-effectiveness of tiotropium in elderly patients with severe asthma using real-world data. , 2020, The journal of allergy and clinical immunology. In practice.
[12] J. Virchow,et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER , 2020, Respiratory Research.
[13] A. Lala,et al. A manifesto of collaborative longitudinal cardiovascular care in heart failure , 2020, Heart Failure Reviews.
[14] C. Gessner,et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). , 2020, Respiratory medicine.
[15] J. Virchow,et al. Extrafine triple therapy in patients with asthma and persistent airflow limitation , 2020, European Respiratory Journal.
[16] J. Fairburn-Beech,et al. Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan , 2020, Current medical research and opinion.
[17] E. Bleecker,et al. Tiotropium Respimat efficacy and safety in asthma: Relationship to age. , 2020, The journal of allergy and clinical immunology. In practice.
[18] H. Watz,et al. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study , 2020, Respiratory Research.
[19] E. Bleecker,et al. Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5. , 2019, Pulmonary pharmacology & therapeutics.
[20] M. Orrell,et al. Bridging the divide between biomedical and psychosocial approaches in dementia research: the 2019 INTERDEM manifesto , 2019, Aging & mental health.
[21] T. Casale,et al. Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. , 2019, The journal of allergy and clinical immunology. In practice.
[22] Kenta Akitsu,et al. Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting β2-agonist in for patients with asthma , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.
[23] C. White,et al. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis , 2018, JAMA.
[24] J. Virchow,et al. Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. , 2017, The journal of allergy and clinical immunology. In practice.
[25] A. Abernethy,et al. Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto for Change. , 2017, Journal of pain and symptom management.
[26] T. Iwanaga,et al. Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. , 2017, Pulmonary pharmacology & therapeutics.
[27] Kenta Akitsu,et al. Effects of the addition of tiotropium on airway dimensions in symptomatic asthma. , 2016, Allergy and asthma proceedings.
[28] E. Bateman,et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. , 2016, Respiratory medicine.
[29] K. Ohta,et al. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study , 2015, PloS one.
[30] E. Pizzichini,et al. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. , 2015, Respiratory medicine.
[31] Y. Nakanishi,et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. , 2013, Pulmonary pharmacology & therapeutics.
[32] H. Kerstjens,et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.
[33] H. Magnussen,et al. Improvements with tiotropium in COPD patients with concomitant asthma. , 2008, Respiratory medicine.